Fosfomycin tromethamine
Based on 15 publication(s) in Google Scholar
Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 78964-85-9
- Formula: C7H18NO7P
- Molecular Weight:259.19
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Fosfomycin tromethamine
More- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- MedComm (2020). 2025 Jan 8;6(1):e70046. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
- Front Cell Infect Microbiol. 2019 Jul 15:9:253. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- ACS Infect Dis. 2024 Aug 9;10(8):2961-2977. [Abstract]
- Microbiol Spectr. 2025 Sep 2;13(9):e0152125. [Abstract]
- Microb Pathog. 2026 Jan:210:108138. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- J Antibiot (Tokyo). 2025 Mar;78(4):265-273. [Abstract]
- J Med Microbiol. 2019 Mar;68(3):493-502. [Abstract]
- Indian J Med Microbiol. 2026 May 14:62:101146. [Abstract]
- bioRxiv. 2025 January 19.
- bioRxiv. 2024 May 10.
All Antibiotic Isoforms
More
Biological Activity
Fosfomycin tromethamine is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis[1].
Fosfomycin tromethamine has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%[1].
Fosfomycin tromethamine displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pharmacokinetic of Fosfomycin Tromethamine in Rats[4]
| Dibekacin Dose (mg) | Vdss (l/kg) | β (min-1) | T1/2 (min) | Urinary recovery (%) |
| 30 | 0.261 | 0.0244 | 28.4 | 85 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fischer 344 rats[3]
-
Dosage:320 mg/kg
-
Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
-
Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
-
Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old)[4]
-
Dosage:120 mg/kg
-
Administration:Intravenous injection; once
-
Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.
Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 78964-85-9
-
Appearance Solid
-
Molecular Weight 259.19
-
Formula C7H18NO7P
-
Color White to off-white
-
SMILES
C[C@@H]1O[C@@H]1P(O)(O)=O.OCC(CO)(N)CO
-
Synonyms
MK-0955 tromethamine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
MedComm (2020)
Novel antibiotics against Staphylococcus aureus without detectable resistance by targeting proton motive force and FtsH. [Abstract]2025 Jan 8;6(1):e70046. PMID: 39781293 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Antibiotics (Basel)
Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]2021 Sep 14;10(9):1110. PMID: 34572692 -
Front Cell Infect Microbiol
Fosfomycin Protects Mice From Staphylococcus aureus Pneumonia Caused by α-Hemolysin in Extracellular Vesicles by Inhibiting MAPK-Regulated NLRP3 Inflammasomes. [Abstract]2019 Jul 15:9:253. PMID: 31380296 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
ACS Infect Dis
Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]2024 Aug 9;10(8):2961-2977. PMID: 39066703 -
Microbiol Spectr
Sub-inhibitory concentrations of fosfomycin enhance Staphylococcus aureus biofilm formation by a sarA-dependent mechanism. [Abstract]2025 Sep 2;13(9):e0152125. PMID: 40689791 -
Microb Pathog
Sub-minimum inhibitory concentrations of fosfomycin enhance Staphylococcus aureus virulence through the agr-PSM pathway. [Abstract]2026 Jan:210:108138. PMID: 41429753 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
J Antibiot (Tokyo)
In vitro assessment of the synergistic effects of cefotaxime, colistin, and fosfomycin combinations against foodborne resistant Escherichia coli and Salmonella isolates. [Abstract]2025 Mar;78(4):265-273. PMID: 39910346 -
J Med Microbiol
In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis. [Abstract]2019 Mar;68(3):493-502. PMID: 30882300 -
Indian J Med Microbiol
Can aztreonam/avibactam combined with fosfomycin be a treatment option for infections caused by NDM-producing Pseudomonas aeruginosa?. [Abstract]2026 May 14:62:101146. PMID: 42140317 -
-
Solvent & Solubility
H2O : 250 mg/mL (964.54 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24. [Content Brief]
[2]. Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47. [Content Brief]
[3]. Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5(9):659-69. [Content Brief]
[4]. Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.8582 mL | 19.2909 mL | 38.5817 mL | 96.4543 mL |
| 5 mM | 0.7716 mL | 3.8582 mL | 7.7163 mL | 19.2909 mL | |
| 10 mM | 0.3858 mL | 1.9291 mL | 3.8582 mL | 9.6454 mL | |
| 15 mM | 0.2572 mL | 1.2861 mL | 2.5721 mL | 6.4303 mL | |
| 20 mM | 0.1929 mL | 0.9645 mL | 1.9291 mL | 4.8227 mL | |
| 25 mM | 0.1543 mL | 0.7716 mL | 1.5433 mL | 3.8582 mL | |
| 30 mM | 0.1286 mL | 0.6430 mL | 1.2861 mL | 3.2151 mL | |
| 40 mM | 0.0965 mL | 0.4823 mL | 0.9645 mL | 2.4114 mL | |
| 50 mM | 0.0772 mL | 0.3858 mL | 0.7716 mL | 1.9291 mL | |
| 60 mM | 0.0643 mL | 0.3215 mL | 0.6430 mL | 1.6076 mL | |
| 80 mM | 0.0482 mL | 0.2411 mL | 0.4823 mL | 1.2057 mL | |
| 100 mM | 0.0386 mL | 0.1929 mL | 0.3858 mL | 0.9645 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.